Hudson Bay Capital Management
NBIX icon

Hudson Bay Capital Management’s Neurocrine Biosciences NBIX Stock Holding History

Hudson Bay Capital Management’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$21.9M Sell
130,000
-265,850
-67% -$39.4M 0.06% 211
2026
Q1 		$52.1M Buy
395,850
+90,850
+30% +$12.1M 0.18% 99
2025
Q4 		$43.3M Buy
305,000
+264,490
+653% +$38.3M 0.14% 131
2025
Q3 		$5.69M Sell
40,510
-37,083
-48% -$5.02M 0.02% 512
2025
Q2 		$9.75M Sell
77,593
-72,787
-48% -$8.35M 0.03% 362
2025
Q1 		$16.6M Buy
150,380
+120,038
+396% +$15.2M 0.05% 292
2024
Q4 		$4.14M Sell
30,342
-9,658
-24% -$1.19M 0.01% 535
2024
Q3 		$4.61M Sell
40,000
-5,000
-11% -$685K 0.02% 428
2024
Q2 		$6.2M Buy
45,000
+15,000
+50% +$2.06M 0.03% 340
2024
Q1 		$4.14M Sell
30,000
-27,500
-48% -$3.76M 0.02% 338
2023
Q4 		$7.58M Buy
57,500
+7,500
+15% +$863K 0.05% 232
2023
Q3 		$5.63M Sell
50,000
-27,500
-35% -$2.9M 0.04% 257
2023
Q2 		$7.31M Buy
77,500
+47,500
+158% +$4.64M 0.05% 227
2023
Q1 		$3.04M Buy
30,000
+19,160
+177% +$1.99M 0.03% 433
2022
Q4 		$1.29M Sell
10,840
-94,160
-90% -$11M 0.01% 666
2022
Q3 		$11.2M Sell
105,000
-65,000
-38% -$6.6M 0.1% 143
2022
Q2 		$16.6M Buy
170,000
+15,000
+10% +$1.38M 0.13% 99
2022
Q1 		$14.5M Buy
155,000
+20,000
+15% +$1.69M 0.2% 78
2021
Q4 		$11.5M Buy
135,000
+55,111
+69% +$5.07M 0.12% 109
2021
Q3 		$7.66M Buy
79,889
+9,889
+14% +$934K 0.1% 205
2021
Q2 		$6.81M Buy
70,000
+5,000
+8% +$479K 0.08% 240
2021
Q1 		$6.32M Sell
65,000
-5,000
-7% -$524K 0.08% 216
2020
Q4 		$6.71M Buy
70,000
+40,000
+133% +$3.86M 0.07% 180
2020
Q3 		$2.88M Buy
+30,000
New +$3.47M 0.04% 308
2020
Q2 		– Sell
-10,000
Closed -$866K – 534
2020
Q1 		$866K Buy
+10,000
New +$979K 0.02% 342
2019
Q3 		– Sell
-30,000
Closed -$2.53M – 459
2019
Q2 		$2.53M Buy
30,000
+25,000
+500% +$2.05M 0.06% 248
2019
Q1 		$441K Buy
+5,000
New +$418K 0.01% 616

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Hudson Bay Capital Management's NBIX Position: Q2 2026 in Review

Hudson Bay Capital Management reduced its Neurocrine Biosciences (NBIX) stake by 67% in Q2 2026, selling an estimated $39.4M and leaving 130,000 shares worth $21.9M. The position accounts for 0.06% of the portfolio, ranked #211.

Hudson Bay Capital Management first reported a position in NBIX in Q1 2019 and has held it in 27 quarters since. The position peaked at $52.1M in Q1 2026. 775 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • Hudson Bay Capital Management held 130,000 shares of Neurocrine Biosciences worth $21.9M as of Q2 2026.
  • Hudson Bay Capital Management sold 265,850 Neurocrine Biosciences shares in Q2 2026, an estimated $39.4M.
  • Neurocrine Biosciences made up 0.06% of Hudson Bay Capital Management's portfolio in Q2 2026, its #211 holding.
  • Hudson Bay Capital Management first reported a position in Neurocrine Biosciences in Q1 2019 and has held it in 27 quarters since.
  • Hudson Bay Capital Management's Neurocrine Biosciences position peaked at $52.1M in Q1 2026.
  • 775 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Hudson Bay Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.